Chronic Inflammatory Demyelinating Polyneuropathy

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a neurological disorder characterized by progressive weakness and impaired sensory function in the arms and legs.

Featured Video

European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second Revision

CIDP

Watch Dr. Peter Van den Bergh, lead author, take you through the highlights of the guideline.

Videos about CIDP

VIEW ALL VIDEOS

20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Polyneuropathy (PATH): a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial

Vera Bril, BSc, FRCPC, MD

University of Toronto,Toronto, Canada

15:31 MIN

CIDP

Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP

DOWNLOAD PDF

Dosing Schedules for IVIg: The Use of an Algorithm as a Suggestion for Personalized Dosing

Michael Lunn, PhD

National Hospital for Neurology and Neurosurgery, Queen Square, London

14:01 MIN

CIDP

Learn how an algorithm could be used to personalize dosing schedules for IVIg.

DOWNLOAD PDF

Improving CIDP Diagnosis: The Challenges of Under and Over Diagnosis

Jeffrey A. Allen, MD

University of Minnesota

12:30 MIN

CIDP

Understand the challenges associated with accurately diagnosing CIDP

DOWNLOAD PDF

The GRIPPER study: Quantifying IVIG Treatment-Related Fluctuations in CIDP Using Daily Grip Strength Measurements

Jeffrey A. Allen, MD

University of Minnesota

12:15 MIN

CIDP

Learn more about grip strength as an outcome measure in CIDP and how it is utilized in the Gripper Study as a daily measure of treatment-related fluctuations in IVIg-treated patients.

DOWNLOAD PDF

NOW PLAYING

15:31

20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Poly...

Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP

NOW PLAYING

14:01

Dosing Schedules for IVIg: The Use of an Algorithm as a Suggestion for Personalized Dosing

Learn how an algorithm could be used to personalize dosing schedules for IVIg.

NOW PLAYING

12:30

Improving CIDP Diagnosis: The Challenges of Under and Over Diagnosis

Understand the challenges associated with accurately diagnosing CIDP

NOW PLAYING

12:15

The GRIPPER study: Quantifying IVIG Treatment-Related Fluctuations in CIDP Using Daily Grip Strength...

Learn more about grip strength as an outcome measure in CIDP and how it is utilized in the Gripper Study as a daily measure of treatment-related fluctuations in IVIg-treated patients.

Our Experts on CIDP

VIEW ALL EXPERTS

Nabil Moumane, MD

Medical Affairs and Pharmacology, CSL Behring

Nabil Moumane, MD

Medical Affairs and Pharmacology, CSL Behring

CIDP
MMN

Nabil Moumane is the Director of Medical Affairs and Pharmacology at CSL Behring.

Richard A. Lewis, MD

Cedars-Sinai Medical Center, Los Angeles, CA, USA

Richard A. Lewis, MD

Cedars-Sinai Medical Center, Los Angeles, CA, USA

CIDP
GBS
MMN

Richard A. Lewis, MD is Professor of Neurology at Cedars-Sinai Medical Center in Los Angeles, California where he directs the EMG laboratory and co-directs the neuromuscular clinical program.

Jeffrey A. Allen, MD

University of Minnesota

Jeffrey A. Allen, MD

University of Minnesota

CIDP
MMN

Dr. Jeffrey Allen is a neuromuscular specialist and clinical investigator at the University of Minnesota in Minneapolis.

Vera Bril, BSc, FRCPC, MD

University of Toronto,Toronto, Canada

Vera Bril, BSc, FRCPC, MD

University of Toronto,Toronto, Canada

CIDP

Vera Bril is a Professor of Medicine (Neurology) at the University of Toronto, Director of Neurology at University Health Network and Mount Sinai Hospital and the Krembil Family Chair in Neurology.

What is Chronic Inflammatory
Demyelinating Polyneuropathy (CIDP)?

What are the symptoms of CIDP?

How is CIDP treated?